Fortunate to speak to colleagues in Brasil / Portuguese about #MM and #CART, #bispecifics. What a unique honor @mmkingt.bsky.social

There's very little published on #rehabilitation in #CAR-T. A short report sharing insights from our service pilot of #physiotherapy input before and after CAR-T @UCLH has been published in eJHaem onlinelibrary.wiley.com/doi/10.1002/...

Single‐centre experience of implementing physiotherapist‐led prehabilitation for chimeric antigen receptor T cell therapy

Introduction This report outlines the evaluation of physiotherapist-led prehabilitation/rehabilitation for recipients of chimeric antigen receptor T (CAR-T) cell therapy. Methods A hybrid approach...

onlinelibrary.wiley.com

So happy to have you in Houston at the #IMF #myeloma meeting to kick off!

Tracy King@mmkingt.bsky.social · 2y ago

On our way

Nurse/AH welcome all to join us @myeloma-society.bsky.social travel safe - c u in Rio! events.jspargo.com/ims24/CUSTOM...

Don't miss this Meet the Expert session on Saturday, September 28 at #IMS24. Register now!➡️ rb.gy/1h136x

T-14 days until #IMS24! @rahulbanerjeemd.bsky.social

Myeloma Society@myeloma-society.bsky.social · 2y ago

Are you ready for #IMS24?🤩 In just a few weeks, professionals from around the globe will gather to explore the latest in #myeloma research. Don’t be left behind! Whether in Rio de Janeiro or virtually, be part of the experience. Register today! ➡️ rb.gy/1h136x

1/ And since we can’t tweet during #IMS24, also worth highlighting CEPHEUS as another LBA! D-VRd vs VRd in ASCT-ineligible #MMsm - large PFS benefit with CD38 addition even if no ASCT. Love simplicity of the last line: ASCT decision-making should not dictate induction choice!

Where are my #myeloma peeps?